Long-acting beta(2) agonists as potential option in the treatment of acute exacerbations of COPD.
Cazzola
Mario
M
Department of Respiratory Medicine, Cardarelli Hospital, Naples, Italy. mcazzola@qubisoft.it
Matera
Maria Gabriella
MG
D000318:Adrenergic beta-Agonists / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000402:Airway Obstruction / Q000188:drug therapy* / Q000209:etiology; D000420:Albuterol / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001993:Bronchodilator Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004983:Ethanolamines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000068759:Formoterol Fumarate; D006207:Half-Life; D006801:Humans; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D000068299:Salmeterol Xinafoate
D000318:Adrenergic beta-Agonists; D001993:Bronchodilator Agents; D004983:Ethanolamines; D000068299:Salmeterol Xinafoate; D000420:Albuterol; D000068759:Formoterol Fumarate